The company on Wednesday said that it is also working urgently to increase manufacturing capacity and supply by ramping up our own production network, as well as actively collaborating with external partners to maximize production of Actemra (Tocilizumab) wherever possible with the goal of increasing its availability.Roche seeks emergency use approval of antibody cocktail to treat COVID-19 patients
The company on Wednesday said that it is also working urgently to increase manufacturing capacity and supply by ramping up our own production network, as well as actively collaborating with external partners to maximize production of Actemra (Tocilizumab) wherever possible with the goal of increasing its availability.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment